Cargando…
Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
BACKGROUND: The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. OBJECTIVE: We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patie...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975863/ https://www.ncbi.nlm.nih.gov/pubmed/27547432 http://dx.doi.org/10.1136/openhrt-2016-000437 |
_version_ | 1782446787400826880 |
---|---|
author | Yasuda, Masakazu Iwanaga, Yoshitaka Kato, Takao Izumi, Toshiaki Inuzuka, Yasutaka Nakamura, Takashi Miyaji, Yuki Kawamura, Takayuki Ikeguchi, Shigeru Inoko, Moriaki Kurita, Takashi Miyazaki, Shunichi |
author_facet | Yasuda, Masakazu Iwanaga, Yoshitaka Kato, Takao Izumi, Toshiaki Inuzuka, Yasutaka Nakamura, Takashi Miyaji, Yuki Kawamura, Takayuki Ikeguchi, Shigeru Inoko, Moriaki Kurita, Takashi Miyazaki, Shunichi |
author_sort | Yasuda, Masakazu |
collection | PubMed |
description | BACKGROUND: The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. OBJECTIVE: We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patients with cardiac sarcoidosis using cardiac MRI. METHODS: We included 81 consecutive patients with cardiac sarcoidosis undergoing cardiac MR. Left ventricular mass and fibrosis mass were calculated, and localisation was analysed using a 17-segment model. Participants underwent follow-up through 2015, and the development of major adverse cardiac events including ventricular tachyarrhythmias was recorded. RESULTS: Increased left ventricular fibrosis mass was associated with increased prevalence of ventricular tachyarrhythmias (p<0.001). When localisation was defined as the sum of late gadolinium enhancement in the left ventricular basal anterior and basal anteroseptal areas, or the right ventricular area, it was associated with ventricular tachyarrhythmias (p<0.001). Kaplan-Meier analysis during a median follow-up of 22.1 months showed that both the mass and localisation groupings for fibrosis were significantly associated with major adverse cardiac events or ventricular tachyarrhythmias and that when combined, the risk stratification was better than for each variable alone (p<0.001, respectively). By Cox-proportional hazard risk analysis, the localisation grouping was an independent predictor for the both. CONCLUSIONS: In patients with cardiac sarcoidosis, both fibrosis mass and its localisation to the basal anterior/anteroseptal left ventricle, or right ventricle was associated with the development of major adverse cardiac events or ventricular tachyarrhythmias. Cardiac MR with late gadolinium enhancement may be useful for improving risk stratification in patients with cardiac sarcoidosis. |
format | Online Article Text |
id | pubmed-4975863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49758632016-08-19 Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis Yasuda, Masakazu Iwanaga, Yoshitaka Kato, Takao Izumi, Toshiaki Inuzuka, Yasutaka Nakamura, Takashi Miyaji, Yuki Kawamura, Takayuki Ikeguchi, Shigeru Inoko, Moriaki Kurita, Takashi Miyazaki, Shunichi Open Heart Heart Failure and Cardiomyopathies BACKGROUND: The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. OBJECTIVE: We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patients with cardiac sarcoidosis using cardiac MRI. METHODS: We included 81 consecutive patients with cardiac sarcoidosis undergoing cardiac MR. Left ventricular mass and fibrosis mass were calculated, and localisation was analysed using a 17-segment model. Participants underwent follow-up through 2015, and the development of major adverse cardiac events including ventricular tachyarrhythmias was recorded. RESULTS: Increased left ventricular fibrosis mass was associated with increased prevalence of ventricular tachyarrhythmias (p<0.001). When localisation was defined as the sum of late gadolinium enhancement in the left ventricular basal anterior and basal anteroseptal areas, or the right ventricular area, it was associated with ventricular tachyarrhythmias (p<0.001). Kaplan-Meier analysis during a median follow-up of 22.1 months showed that both the mass and localisation groupings for fibrosis were significantly associated with major adverse cardiac events or ventricular tachyarrhythmias and that when combined, the risk stratification was better than for each variable alone (p<0.001, respectively). By Cox-proportional hazard risk analysis, the localisation grouping was an independent predictor for the both. CONCLUSIONS: In patients with cardiac sarcoidosis, both fibrosis mass and its localisation to the basal anterior/anteroseptal left ventricle, or right ventricle was associated with the development of major adverse cardiac events or ventricular tachyarrhythmias. Cardiac MR with late gadolinium enhancement may be useful for improving risk stratification in patients with cardiac sarcoidosis. BMJ Publishing Group 2016-08-01 /pmc/articles/PMC4975863/ /pubmed/27547432 http://dx.doi.org/10.1136/openhrt-2016-000437 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Heart Failure and Cardiomyopathies Yasuda, Masakazu Iwanaga, Yoshitaka Kato, Takao Izumi, Toshiaki Inuzuka, Yasutaka Nakamura, Takashi Miyaji, Yuki Kawamura, Takayuki Ikeguchi, Shigeru Inoko, Moriaki Kurita, Takashi Miyazaki, Shunichi Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis |
title | Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis |
title_full | Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis |
title_fullStr | Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis |
title_full_unstemmed | Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis |
title_short | Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis |
title_sort | risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac mri in patients with cardiac sarcoidosis |
topic | Heart Failure and Cardiomyopathies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975863/ https://www.ncbi.nlm.nih.gov/pubmed/27547432 http://dx.doi.org/10.1136/openhrt-2016-000437 |
work_keys_str_mv | AT yasudamasakazu riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT iwanagayoshitaka riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT katotakao riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT izumitoshiaki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT inuzukayasutaka riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT nakamuratakashi riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT miyajiyuki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT kawamuratakayuki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT ikeguchishigeru riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT inokomoriaki riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT kuritatakashi riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis AT miyazakishunichi riskstratificationformajoradversecardiaceventsandventriculartachyarrhythmiasbycardiacmriinpatientswithcardiacsarcoidosis |